Press Releases

Rare Disease Company Coalition Names Kathryn Handler Executive Director

Former U.S. Senate HELP Committee Deputy Health Policy Director brings extensive federal health policy experience to RDCC

WASHINGTON, D.C. — The Rare Disease Company Coalition (RDCC) today is pleased to announce that Kathryn Handler has joined the organization as Executive Director. Handler brings extensive experience in federal health policy, including senior roles on the Senate Committee on Health, Education, Labor, and Pensions (HELP) and at the Department of Health and Human Services (HHS).

Most recently, Handler served as Deputy Health Policy Director for the Senate HELP Committee, where she oversaw the Committee’s health policy work and managed a team of policy professionals. Her portfolio included Food and Drug Administration (FDA) policy for drug and biological product regulation, biomedical research, and other public health issues. She previously held policy roles at HHS, working on matters involving FDA, other federal health agencies, and cross-agency coordination.

“Kathryn understands how policy decisions shape the environment in which rare disease companies discover, develop, and deliver therapies,” said Chris Porter, Chair of RDCC. “Her experience navigating complex legislative and regulatory issues, coupled with her collaborative leadership style, will be a tremendous asset as our coalition continues advocating for patients and the companies working to develop treatments for them.”

“I’m honored to join RDCC and work alongside companies that are taking on some of the most difficult challenges in medicine,” said Handler. “Rare disease innovation demands policies that account for the unique realities of working with small patient populations. I look forward to listening to our members and partners, building on the coalition’s momentum, and advancing thoughtful solutions that help promising therapies reach patients.”

Handler supported negotiations related to the 21st Century Cures Act and played a leading role in developing and negotiating public health legislation, including the PREVENT Pandemics Act. Across her federal service, she has worked with congressional offices and officials from multiple administrations to advance complex policy initiatives.

As Executive Director, Handler will guide RDCC’s efforts to educate policymakers on the distinct challenges facing rare disease innovators and advocate for consistent, sustainable policies that promote investment in new therapies and patient access.

###

About the Rare Disease Company Coalition (RDCC): Founded in May 2021, the Rare Disease Company Coalition represents life science companies committed to discovering, developing and delivering rare disease treatments for the patients we serve. As an education and advocacy-focused coalition of companies, our goal is to inform policymakers of the unique challenges and promises of rare disease drug discovery, development and manufacturing for small population sizes so that critical innovation can continue and positive changes can be enacted for the rare disease community. To achieve this goal, we use our unified voice to advocate for long-term, consistent, equitable and sustainable government policies that enable life science companies to continue to bring hope and provide access to approved treatments to people living with rare diseases. For more information, please visit rarecoalition.com.